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Abstract
Natural killer (NK) cells are an essential component of the innate immune system, and they 
play a crucial role in immunity against malignancies. Recent advances in our understanding 
of NK cell biology have paved the way for new therapeutic strategies based on NK cells for 
the treatment of various cancers. In this section, we will focus on NK cell immunotherapy, 
including the enhancement of antibody‐dependent cellular cytotoxicity, the manipulation 
of receptor‐mediated activation, inclusion criteria based on killer cell immunoglobulin‐like 
receptor (KIR) ligand mismatches, and adoptive immunotherapy with ex vivo expanded 
chimeric antigen receptor (CAR)‐engineered or engager‐modified NK cells. In contrast 
to T lymphocytes, donor NK cells do not attack any recipient tissues based on allogeneic 
human leukocyte antigens (HLAs), suggesting that NK‐mediated antitumor effects may be 
achieved without the risk of graft‐versus‐host disease (GvHD). Despite reports of clinical 
efficacy, the application of NK cell immunotherapy is limited. Developing strategies for 
manipulating NK cell products, host factors, and tumor targets are thus current subjects of 
diligent study. Research into the biology of NK cells has indicated that NK cell immunother‐
apy has the potential to become the forefront of cancer immunotherapy in the coming years.
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1. Introduction
Natural killer (NK) cells have been used in clinical studies in order to treat various malignan‐
cies. Missing‐self is one of the mechanisms of the NK cell response that works by the detection 
of the loss of autologous major histocompatibility complex (MHC) class I expression.
We will mention four elements of NK cells in this chapter: (1) mechanisms of NK cells; 
(2)  activation of NK cells; (3) inclusion criteria based on KIR ligand mismatches; and (4) genetic 
modifications ex vivo.
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
NK cells, which are thought to have emerged much later than B cells and T cells based on the 
evolutionary convergence of variable receptors, rarely cause autoimmune diseases. We will 
introduce the applicability of the NK cell to cancer treatment.
2. Activation of NK cells
NK cell‐based immunotherapy has been explored for decades. Several animal experiments indi‐
cated the potential efficacy of NK cells in cancer treatment [1–3]. However, ex vivo NK cell expan‐
sion techniques have been insufficient regarding the numbers of cells, purity and  antitumor activity 
to use in clinical settings. NK cells comprise only a minor population (i.e., 5–15% of peripheral 
lymphocytes), and only a small number of NK cells is isolated after a typical apheresis procedure. 
For example, approx. 77.8 ± 14.4 × 109/L (range 62.7–95.9 × 109/L) of leukapheretic products are the 
result of a single apheresis of peripheral blood in a normal adult human with a mean percentage 
of lymphocytes of 59.8% ± 6.1 (range 53.9–66.4%), and subsequently 5–10 × 108 NK cells can be 
obtained [4]. On the other hand, at least 2 × 107/kg or 6 × 106–6.5 × 109/body NK cells are required 
for each effective injection with multiple  administrations [5, 6]. In addition, the reported engraft‐
ment period of NK cells was 2–189 days (median 10 days), which showed no correlation with the 
number of NK cells administered [7]. The NK cell infusion should thus be repeated in order to 
maintain a sufficient number of NK cells meeting clinical requirements, but this would be a burden 
on patients.
Scientists have been working to develop various methods for proliferating NK cells ex vivo 
with high cytotoxicity and high purity. Several studies used an anti‐CD3 antibody (clone: 
OKT3) in the first few days of culture for the activation of autologous T cells to help the NK 
cell expansion, subsequently producing high numbers of undesirable T cells or NKT cells 
in the final product [8–10]. However, particularly in haploidentical NK cell transplantation, 
T cells must be excluded prior to the infusion in order to prevent graft versus host disease 
(GvHD). Other studies removed CD3+ cells by magnetic beads with or without CD56‐positive 
selection at the beginning of culture [11–13].
To acquire highly purified and expanded NK cells, an initial efficient depletion (<1%) of CD3+ 
cells and a relatively long‐term culture (over 12 days) seem to be essential [12, 13]. Because 
only a minor fraction of circulating NK cells is reactive to target cells (tumor cells) in vitro, 
primary NK cells show insufficient cytotoxicity [14]. Various types of stimulation have thus 
been reported to enable NK cells to achieve their full effector potential, such as interleukin 
(IL)‐15 produced by dendritic cells (DCs) [15] or macrophages [16], IL‐2 [17], IL‐12 [18], IL‐18 
[19] and IL‐21 [20]. Currently, the additional cytokines used in the cultivation of NK cells 
include IL‐2, IL‐15, and IL‐21. IL‐2, IL‐15, and IL‐21 share the receptor subunits IL‐2/15Rβ and 
common γ chain [21] on the NK cell surface and have a synergetic effect. Use of IL‐2 combined 
with IL‐15 for cultivation leads to good viability and good proliferation of NK cells [22]. IL‐2 
is also important for NK cell infiltration and killing, and IL‐15 is important for both NK cell 
maturation and survival [21]. IL‐2 and IL‐15 induce the expression of KIRs and activating 
receptors (NKG2D and NKp44) on NK cell surface [23]. IL‐21 modifies the expression of killer 
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cell immunoglobulin‐like receptors (KIRs) and NKp44 by reducing expression of DAP‐12, 
subsequently promote cell maturation, the ability of killing and survival [22, 23]. Several 
experiments used feeder cells to provide essential stimulation for NK cell cultivation through 
cytokine production or cell‐to‐cell contact [20, 23, 24]. The various cytokines and feeder cells 
used in some clinical trials are mentioned in a later section of this article.
2.1. Killer cell immunoglobulin‐like receptors (KIRs)
NK cells express KIRs, most of which are inhibitory (partially activating) receptors that rec‐
ognized MHC class I molecules. In the 1980s, KIRs were first described as explaining the NK 
cell‐mediated rejection of allogeneic bone marrow transplants from a homozygous donor to 
a hemizygous host in lymphoma and in F1‐hybrid anti‐parental resistance in a rodent model 
[25]. In these situations, the graft fails to express at least one MHC class I allele of the host, 
and NK cells are highly capable of identifying the difference, thus causing rejection. This can 
be explained by the concept that NK cells have inhibitory receptors and begin to attack target 
cells if they do not express ligands that interact with the specific inhibitory receptors. This 
phenomenon was termed the “missing‐self hypothesis”, which is now accepted as one of the 
complex target recognition mechanisms of NK cells.
2.1.1. Regulation of NK cell activity
The activation of NK cells is regulated by various receptors including KIRs, CD94–NKG2 family, 
leukocyte immunoglobulin‐like receptors (LILRs), natural cytotoxicity receptors (NCRs), and 
FcγRIIIa (CD16) [26–28]. Among these receptors, KIRs, CD94/NKG2A heterodimers, and LILRs 
belong to the large family of inhibitory receptors of MHC class I, mediating NK cell function by 
signaling through intracytoplasmic immunoreceptor tyrosine‐based inhibition motifs (ITIMs) 
[29]. Each NK cell has a threshold of activation through a balance of total stimulation between 
inhibitory and activating signals [30] (Figure 1). In other words, NK cells selectively kill tar‐
get cells that down‐regulate MHC class I molecules and/or up‐regulate other activating ligands 
[28] such as MHC class I chain (MIC)‐related antigens MICA, MICB and UL‐16 binding protein 
(ULBP). MICA, MICB, ULBPs are ligands of NKG2D homodimer, which belong to C‐type lectin 
receptor NKG2 family expressed on the surface of NK cells and CD8+ T‐lymphocytes. NKG2A/
CD94 and NKG2B/CD94 heterodimers transmit inhibitory  signals, while NKG2C/CD94, 
NKG2E/CD94, NKG2H/CD94 heterodimers and NKG2D homodimer are activating receptors.
2.1.2. Genetics of KIRs
The KIR gene family includes 14 loci (KIR2DL1, KIR2DL2/3, KIR2DL4, KIR2DL5A/B, KIR2DS1, 
KIR2DS2, KIR2DS3, KIR2DS4, KIR2DS5, KIR3DL1/S1, KIR3DL2, KIR3DL3 and two pseudo‐
genes, KIR2DP1 and KIR3DP1) [31]as shown in Table 1. These loci are located on chromosome 
19q13.4, which is known as the leukocyte receptor cluster (LRC); each haplotype has 9–15 KIR 
genes in a row [32]. Different NK cells within individuals each express a subset of the available 
KIR repertoire, leading to an allelic polymorphism of KIRs. Based on studies of KIR genotype 
variation, two major KIR haplotype groups termed the groups ‘A’ and ‘B’ are defined [33].
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Inhibitory Ligands Ligand missing Notes
KIR2DL1 HLA‐C2 group (Cw2, C*0307,Cw4, 
Cw5, Cw6, C*0707, C*0709, C*1204, 
C*1205, Cw15, C*1602, Cw17, Cw18)
HLA‐C1/C1
KIR2DL2 HLA‐C1 group (Cw1, Cw3, Cw7, Cw8, 
Cw12, Cw13, Cw14, C*1507, C*1601/4)
HLA‐C2/C2(except for 
C*02, *05) and HLA‐B46, 
B73 negative
HLA‐B46, B73
HLA‐C2(C*02, C*05)(weak interaction)
KIR2DL3 HLA‐C1 group (Cw1, Cw3, Cw7, Cw8, 
Cw12, Cw13, Cw14, C*1507, C*1601/4)
HLA‐C2/C2 and HLA‐
B46, B73 negative
HLA‐B46, B73
KIR3DL1 HLA‐Bw4 epitope(including HLA‐A23, 
A24, A32)
HLA‐Bw6/Bw6 and 
HLA‐A23/24/32 negative
Expression level: *01502, *020 
> *001, *007 >*004
KIR3DL2 HLA‐A03, A11(+ EBNA peptide),HLA‐
B27 dimer
HLA‐A03, A11 negative, 
free of EBV
*001 is homo‐dimer A03/A11 
could not promote NK cell 
Licensing
KIR2DL5B Unknown
KIR2DL5T Unknown
Activating Ligands Ligand missing Notes
KIR2DS4 HLA‐A*1102,(A*1101, C*0304, C*0501) HLA‐A*1102 negative
KIR2DS1 HLA‐C2 HLA‐C1/C1
KIR2DS2 Unknown(HLA‐C1?)
KIR3DS1 Unknown(HLA‐B*2705?)
KIR2DS3/5 Unknown
KIR2DL4 HLA‐G
Others Ligands Ligand missing Notes
KIR2DP1 − − Pseudogene
KIR3DP1 ‐ ‐ Pseudogene
Table 1. Human KIRs.
Figure 1. The mechanisms of cytotoxicity by NK cells.
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Each haplotype is separated into two regions: the centromeric half (Cen) and the telomeric 
half (Tel). Cen and Tel motifs can be divided into Cen‐A, Cen‐B and Tel‐A, Tel‐B by the KIR 
genes they contain. Haplotype A is a combination of Cen‐A and Tel‐A, which consists of 
mainly inhibitory KIRs (KIR3DL3, 2DL3, 2DL1, 3DL1, 2DS4, 3DL2 and two pseudogenes). 
Other combinations are termed Haplotype B (such as Cen‐A and Tel‐B or Cen‐B and Tel‐B), 
composed of a large variation of genes characterized by the presence of more activating KIRs. 
All individuals can be categorized according to their haplotype: A/A, which is homozygous 
for group A haplotypes, or B/x, which contains either one (A/B) or two (B/B homozygotes) 
group B haplotypes[34]. As a consequence of this genetic variation, several studies report that 
donor‐derived NK cells can mediate the graft‐versus‐leukemia (GVL) effect or even the graft‐
versus‐tumor (GVT) effect after allogeneic hematopoietic cell transplantation (HCT) [34–36]. 
These are the results of a KIR‐ligand mismatch, the details of which are described later in 
this article.
2.1.3. KIRs subtypes
KIRs are type I transmembrane glycoproteins expressed on the surface of NK cells, composed 
of two (2D) or three (3D) extracellular Ig‐like domains and a cytoplasmic short (activating) or 
long (inhibitory) tail [31]. The length of the intracytoplasmic part determines the function; for 
example, receptors with long cytoplasmic tails with one or two ITIMs that bind to phospha‐
tase SHP‐1, 2 allow the transduction of inhibitory signals through its dephosphorylation. In 
contrast, receptors with short cytoplasmic tails possess a positively charged residue (lysine) 
in the transmembrane domain that enables it to associate with adaptor proteins including 
DAP12 and process the immunoreceptor tyrosine‐based activation motifs (ITAMs) [29]. There 
is one exception: KIR2DL4, with a long cytoplasmic tail, binds to the activation motif of FcεRIγ 
and thus seems to transmit the activating signal [31].
MHC class I molecules are well‐known ligands for KIRs, but HLA‐C molecules, in particu‐
lar, are the main ligands contributing greatly to NK cell activity. Polymorphisms in amino 
acids at positions 77 and 80 of HLA‐C show specificity for its target KIRs. Group 1 HLA‐C 
ligands (C1) include allele‐encoded molecules with serine and asparagine (Ser77 and Asn80), 
whereas group 2 ligands (C2) are characterized by allele‐encoded molecules with asparagine 
and lysine (Asn77 and Lys80). C1 epitopes bind specifically to KIR2DL2/3, and C2 epitopes 
are ligands for KIR2DL1 [37]. However, it was shown that KIR2DL2/3 might also bind to 
certain HLA‐C2 epitopes (C*0501, C*0202, C*0401) and some HLA‐B epitopes (HLA‐B*4601, 
B*7301) with very low affinity [38].
Among the inhibitory KIRs, KIR2DL1 results in a stronger inhibition compared to the KIR 
2DL2/3 [38]. The third inhibitory KIR is KIR3DL1, which binds to HLA‐Bw4 epitopes and a 
subset of HLA‐A epitopes (A*23, A*24, and A*32). All HLA‐B have either the Bw4 or Bw6 
epitope, but only the Bw4 epitope is a ligand for KIRs [39]. KIR3DL2 is a framework gene, 
and it recognizes HLA‐A*03 and HLA‐A*11 with a low level of inhibition [40]. Although 
haplotype A includes only a single activating KIR (2DL4), at least two to five activating KIR 
genes (2DS1, 2DS2, 2DS3, 2DS5 and 3DS1) are subject to haplotype B. However, KIR2DS1 
alone is now confirmed to have matched ligand HLA‐C2 with lower avidity compared to 
KIR2DL1 [41].
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2.2. Death Ligands
NK cells express members of the tumor necrosis factor (TNF) superfamily, the so‐called 
death ligands. The cognate of the receptor on target cells by these ligands on NK cells — 
which include TNF‐related apoptosis‐inducing ligand (TRAIL), Fas ligand (FasL) and TNF‐
like weak inducer of apoptosis (TWEAK) — results in classical caspase‐dependent apoptosis 
[42, 43]. In the TRAIL/TRAIL receptor system, at least five receptors have been identified and 
two of them, TRAIL‐R1 (DR4) and TRAIL‐R2 (DR5), contain cytoplasmic death domains and 
are able to transduce an apoptotic signal [44]. Other TRAIL receptors — TRAIL‐R3 (DcR1) 
and TRAIL‐R4 (DcR2) and a soluble receptor called osteoprotegerin (OPG: TRAIL‐R5) — 
lack a death domain, but they are dedicated as decoy receptors to regulate TRAIL‐mediated 
cell death [45]. In target cell expressing TRAIL receptors, the ligation of TRAIL can lead to 
the activation of caspase‐8 and subsequently caspase‐3 to induce apoptosis [46, 47]. TRAIL 
is up‐regulated after the stimulation of interferon‐gamma (IFN‐γ) in vitro [48, 49] and also 
in vivo, which demonstrates that TRAIL is required for the IFN‐γ‐mediated prevention of 
tumors [50].
FasL is expressed on activated NK cells and cytotoxic T lymphocytes (CTLs) [42]. Although 
it is known that FasL is expressed on NK cells at a low level, significant amounts are stored 
intracellularly [51]. An activating signal of rodent NK1.1 up‐regulated the expression of 
FasL [52]. After FasL has bound to Fas, the Fas associated with two specific proteins, Fas‐ 
associated death domain (FADD) and caspase‐8, to form the death‐inducing signal complex 
(DISC). Fas is expressed on various tissues, but the molecule is downregulated in cancers 
during its progression [53]. NK cells are capable of directly inducing Fas expression on 
tumor cells via IFN‐γ secretion, and NK cells show cytotoxicity to tumor cells expressing 
Fas [45].
2.3. Perforin and granzyme
Cytolytic killing using perforin and granzyme is a major mechanism in the elimination of 
infected cells and tumor cells by NK cells. NK cells contain cytoplasmic granules  including 
perforin (a membrane‐disrupting protein) and granzyme (a family of serine proteases). Once 
NK cells recognize target cells, they form an immunological synapse, and the secretory gran‐
ules fuse with the presynaptic membrane and release perforin and granzyme into the syn‐
aptic cleft. Released perforin provides transmembrane pores on the target cell and enables 
granzyme to diffuse into the cell. Granzyme then initiates the apoptosis of the target cells, 
and the NK cells detach from the dying cells and can interact with other target cells to accom‐
plish serial killing [54]. The release of such granules stored in the NK cells is dependent on 
the polarization of both microtubules and actin filaments in the cytoskeleton. The increase of 
intracellular calcium concentration triggered by a positive balance of activating and inhibitory 
signals initiate the rapid move of microtubule‐organizing center (MTOC) in the cytoplasm 
towards the target cell, and then cytotoxic granules migrate along the MTOC [54]. Granules 
fuse with the presynaptic membrane, subsequently, the lytic granules can be released at the 
NK cell‐target cell interface[55] (Figure 2).
Natural Killer Cells72
3. NK cells for clinical use
3.1. Sources of NK cells
There are several options for sources of NK cell therapy, including peripheral blood mono‐
nuclear cells (PBMCs), umbilical cord blood (UCB), bone marrow (BM), cell lines, human 
embryonic stem cells (hESCs), and induced pluripotent stem cells (iPSCs).
3.1.1. Peripheral blood mononuclear cells (PBMCs)
PBMCs are the most common source of NK cells, and PBMCs can be collected by apheresis or 
a specific gravity centrifugal method (e.g., Ficoll separation). However, the percentage of NK 
cells in PBMCs is low (5–20%), and because there is a limit on the number of cells that can be 
recovered from a donor by lymphocyte apheresis, it is not possible that a sufficient number 
of NK cells for killing the target can remain in the recipient [7]. That is, in order to stay in the 
recipient’s body until the target cells are killed, it is necessary to collect peripheral blood fre‐
quently, which is a heavy burden on the patient.
Numerous methods for amplification cultures of NK cells have been reported. Stem cell 
mobilization is a process whereby stem cells (CD34+cells) are stimulated out of the bone 
marrow space (e.g., the hip bones and the chest bone) into the bloodstream, and granulo‐
cyte‐colony stimulating factor (G‐CSF) is widely used as a drug for harvesting peripheral 
blood stem cells from patients or healthy people. Another drug, Plerixafor [56], a CXCR4 
Figure 2. Interaction of an NK cell with a target cell.
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antagonist approved in 2008, has an excellent mobilization effect in combination with G‐CSF 
[57, 58].
An increase in a number of CD34‐positive cells harvested by mobilization reduces the num‐
ber of apheresis sessions required for cell therapy, which may reduce the burden on patients. 
When allogeneic hematopoietic stem cells are used, GVHD in the acute phase, which is 
thought to be caused by T‐cell contamination, exists as a problem to be overcome. There is 
also a report that the induction of myeloid‐derived suppressor cells (MDSCs) by the adminis‐
tration of G‐CSF reduces the frequency of GVHD. It is important to note that MDSCs suppress 
T‐cell function through an arginine depletion by arginase‐1, the production of reactive oxygen 
species, and the induction of Treg cells [59, 60].
3.1.2. Bone marrow (BM)
Bone marrow aspiration removes a small amount of bone marrow fluid through a needle put 
into a bone under general anesthesia. Compared to apheresis, it is very rarely used as a start‐
ing material because of its high invasiveness to donors.
3.1.3. Umbilical cord blood (CB)
Hematopoietic reconstitution for Fanconi anemia treatment using cord blood was first per‐
formed in 1988 by Gluckman et al. [61]. Since then it has been widely accepted as a source of 
hematopoietic stem cells when autologous blood is not recommended or readily available. 
Cord blood (CB) can be donated to public CB banks for use by any patient worldwide for 
whom it is stored for potential autologous or family use. The majority of CB products used 
today are for hematopoietic stem cell transplantation and are accessed from public banks.
Cord blood presents no harm to the donor at the time of collection, and the frozen storage of 
collected samples is possible. In addition, cord blood of various blood types is classified and 
preserved in umbilical cord blood banks. When umbilical cord blood is used as the source 
of therapeutic NK cells, it is highly tissue‐compatible according to the patient’s blood type 
and accompanying transplantation. It is easy to select blood type‐specific umbilical cord 
blood, with little side effects. In addition, it is possible to minimize the risk of GVHD from the 
absence of T cells [62–64]. As with PBMCs, a growth culture is essential because the amount 
of NK cells that can be obtained from a single CB sample is not an amount that can expect to 
provide a therapeutic effect.
3.1.4. Embryonic stem cells and induced pluripotent stem cells (ES/iPS)
Another possible source of NK cells is human embryonic stem cells (hESCs) and induced plu‐
ripotent stem cells (iPSCs). A differentiation/expansion culture from hESCs and iPSCs to NK 
cells is a regimen requiring more sophisticated technology compared to the PBMCs and UCB 
described above. The differentiation process of human iPSCs is divided into three stages of 
“maintenance amplification”, “structure construction”, and “differentiation induction”. The 
culturing step is to generate CD34+ hematopoietic progenitor cells from hESCs and iPSCs and 
then differentiate these cells into NK cells.
Natural Killer Cells74
A preclinical demonstration that NK cells can be separated from the sources of these plu‐
ripotent stem cells has been described [65, 66]. However, that demonstration enabled efficient 
proliferation by using mouse stromal cells as feeder cells, and the involvement of heterolo‐
gous cells may limit clinical application. As with UCB, advances in the development of safe, 
effective and standardized clinical‐grade manufacturing protocols will provide opportunities 
to develop ready‐made personalization and immunogenic cell therapy.
3.1.5. Cell lines
The cell lines that have been derived from NK cells are NK‐92, NK‐YS, KHYG‐1, NKL, NKG, 
SNK‐6, and IMC‐1 cells [67], and several research groups are exploring the possibilities of 
using these cell lines for therapeutic applications. The primary advantage of an NK cell line 
is that it is “ready to use”, and it is possible to establish comprehensive standardization and 
characterization of the cell source by using the master cell bank. The cell therapy product is 
thus considered to be an attractive merit in manufacturing. Moreover, a more homogeneous 
population is obtained compared to that from peripheral blood, and its homogeneous charac‐
ter is another advantage when performing a genetic modification operation.
NK cell line has been applied to genetic modification technology for expressing intracellular 
IL‐2 for the forced expression of CD16, natural cytotoxicity receptor (NCR), chimeric antigen 
receptor (CAR) and NK cell activation [68, 69]. The most widely clinically used cell line is the 
NK‐92 cell line, which is cytotoxic to a wide range of malignant cells [70, 71]. NK‐92 cells express 
the receptor but hardly express KIR, NKp44 or CD16. NantKWest (Culver City, CA, USA) con‐
ducts clinical trials using NK‐92 cells (Neukoplast™) and has completed a Phase 1 study (U. 
S. National Clinical Trial [NCT] #00900809 and NCT #00990717). Moreover, the company has 
begun phase 1 and phase 2 trials of haNK (high‐affinity NK cells) [72] engineered to express 
CD16 (NCT #02465957 and NCT #03027128). In addition, as another attempt, the development of 
CAR‐TNK expressing CD7 or CD33 has been advanced (NCT #02944162 and NCT #02742727).
3.2. Manufacturing method
The number of NK cells contained in a collectable amount of UCB or peripheral blood is not 
enough to achieve a clinical therapeutic effect. A long‐term culture method is necessary to 
overcome this problem. For starting material, T cells and/or B cells are removed with mag‐
netic beads to increase the purity of NK cells. This is also to prevent the proliferation of T cells 
caused by IL‐2 during the culture period of NK cells and to avoid lower purity of the final 
product [8, 73].
In addition to the important cytokine IL‐2, there are IL‐15, which is necessary for both the 
maturation and survival of NK cells [21]. IL‐2 and IL‐15 share the same receptor component 
IL‐2/15Rβ and a common γ chain, and they are used in a culture method without the use of 
feeder cells [74, 75]. IL‐21 [76], a member of the IL‐2 cytokine family, is a potent immunostim‐
ulatory cytokine that shows diverse regulatory effects on NK cells, T cells and B cells [77, 78] 
and also has the effect of enhancing rituximab‐mediated antibody‐dependent cell  mediated 
cytotoxicity (ADCC) of mantle cell lymphoma [79]. In addition, there is a culture method 
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using feeder cells to efficiently expand NK cells ex vivo. As feeder cells, monocytes, irradiated 
PBMCs, the K562 cell line and a genetically modified cell line are used.
For example, there are systems using a co‐culture with NK cells and monocytes [80], with 
CB CD34+ cells and bone marrow stromal cells [81], or K562 cells transfected with IL‐21 [82]. 
There is also a completely closed culture using Epstein‐Barr virus‐transformed lymphoblas‐
toid cell lines [83]. Thus, the use of feeder cells is an important method for securing a number 
of cells that can be expected to have a therapeutic effect. However, because of the problem of 
infectious disease risk presented by the use of an allogeneic feeder, the regulatory hurdles in 
the manufacture of pharmaceutical products are high [84].
To overcome this problem, Yonemitsu et al. reported a method of culturing highly acti‐
vated NK cells with ≥90% purity from PBMCs in a completely closed and feeder‐free system 
under the good manufacturing practices (GMP) [13]. As another feeder‐free culture method, 
Spanholtz and colleagues reported a culture method that achieved amplification efficiency 
and high purity of 10,000 times or more in 6 weeks from UCB CD34+ hematopoietic stem cell 
(HSCs), using a closed system process based on GMP [85]. Knorr and colleagues reported dif‐
ferentiation induction from CD34+ hematopoietic progenitor cells produced under feeder‐free 
conditions to cytotoxic NK cells [86].
3.2.1. NK cell‐based immunotherapy: autologous cells
Clinical trials using autologous NK cells have been performed targeting solid tumors such as 
colorectal cancer, non‐small cell lung cancer, melanoma, kidney cancer and esophageal can‐
cer [87–89]. In general, autologous NK cell therapy is safe without side effects such as GvHD 
[87], but its therapeutic effect is limited to some cancer types [74]. An activation culture with 
IL‐2 and OKT3 or Hsp70 has been reported to be able to efficiently induce the proliferation of 
NK cells [74], in particular, the retronectin culture method of Sakamoto et al. showed a high 
amplification efficiency (about 4720‐fold) [89].
3.2.2. NK cell‐based immunotherapy: allogeneic cells
Allogeneic NK cell products are used for the treatment of malignant tumors such as leukemia, 
renal cell carcinoma, colorectal cancer, and lymphoma. The major risk of allogeneic NK cell 
transplantation is the onset of GvHD. Measures against GvHD include the use of immunosup‐
pressive agents, injection of high‐purity NK cells by CD3 depletion, and the selection of donors 
consistent with the host HLA [74, 75]. In the case of haploidentical donors and recipients, to 
avoid GvHD, it is necessary to strictly perform T‐cell depletion. In many studies, CD56+ is 
enriched after the removal of CD3+ T cells [17, 90, 91]. In cases of an allogeneic type, HLA typ‐
ing and confirmation of KIR by flow cytometry are carried out, particularly in order to select the 
optimum donor. For details on the selection criteria, please refer to a later section of this article.
3.2.3. Synergistic effect: antibody drugs
An antibody drug is, in short, a medicine that functions based on the specificity with which an 
antibody recognizes an antigen. The characteristics of antibody drugs are high specificity (low 
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toxicity) and high stability in vivo. The antibody binds only to the target antigen, and not to 
any other, which leads to the intended medicinal effect with only rare unexpected side effects. 
Antibodies are present at a stable level in the blood, and antibody medicines can also be 
detected at a stable level in the blood for a long period after administration, and they can exert 
their medicinal effects over a long term. More than 50 antibody drugs have been approved in 
Japan, the U.S. and Europe. Target diseases include cancer, rheumatoid arthritis and psoriasis, 
but most of the targets are cancers. One of the action mechanisms of antibody drugs used to 
treat cancer is ADCC, in which NK cell plays a central role. Table 2 shows FDA‐approved 
antibodies for ADCC to treat cancer.
ADCC mediated by NK cells begins with the recognition of antibodies bound to target cells. 
NK cells express two Fc receptors, CD16a (FcγRIIIa) [92] and CD32c (FcγRIIc) [93]. These Fc 
receptors recognize and bind to IgG1 and IgG3 and have a high affinity for IgG3 [94]. NK cells 
that recognize the antibody on the target cells transmit their signals intracellularly and kill 
the cells.
The signaling of human CD16 is mediated via FcεRIγ, CD3ζ, or FcεRIγ‐CD3ζ heterodimer. 
These molecules contain an ITAM and are phosphorylated when the antibody binds to CD16 
[42]. CD32c (FcγRIIc) contains an ITAM‐like sequence in the cytoplasmic domain (which is 
Drug name Trade name Type Target Cancers Approved year
Rituximab Rituxan Chimeric IgG1κ CD20 Non‐Hodgkin)s B‐cell 
lymphomas Chronic 
lymphocytic leukemia
1997
MabThera
Trastuzumab Herceptin Humanized IgG1κ HER2 Adenocarcinoma 
of the stomach or 
gastroesophageal junction
1998
Breast cancer
Alemtuzumab Campath Humanized IgG1κ CD52 B‐cell chronic lymphocytic 
leukemia
2001
Cetuximab Erbitux Chimeric IgG1κ EGFR Colorectal cancer 2004
Head and neck cancer
Ofatumumab Arzerra Human IgG1κ CD20 Chronic lymphocytic 
leukemia
2009
Pertuzumab Perjeta Humanized IgG1κ HER2 Breast cancer 2012
Obinutuzumab Gazyva Humanized IgG1κ CD20 Chronic lymphocytic 
leukemia
2013
Follicular lymphoma
Dinutuximab Unituxin Chimeric IgG1κ GD2 Neuroblastoma 2015
Daratumumab Darzalex Humanized IgG1κ CD38 Multiple myeloma 2015
Elotuzumab Empliciti Humanized IgG1κ SLAMF7 Multiple myeloma 2015
Table 2. FDA‐approved antibodies for ADCC to treat cancer.
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similar to that of FcγRIIa), suggesting that it transmits a signal via SRC‐SYK (the SRC family 
of kinases and spleen tyrosine kinase [SYK]) signaling pathways [95]. However, the expres‐
sion of CD32c was less than half of that of NK cells [96, 97]. Many studies focusing on CD16 
have thus been conducted.
Several genetic polymorphisms of CD16 exist. Among them, the amino acid at position 158 
has been shown to be important for the strength of the affinity for antibodies. The affinity 
depends on whether the amino acid at position 158 is phenylalanine or valine, and the valine 
type (158 V) has a higher affinity for the Fc of IgG. A number of reports have indicated that 
differences in the affinity for antibodies are correlated with therapeutic effects, and many 
studies have analyzed the clinical responsiveness of this gene polymorphism and antibody 
therapy. Cartron et al. examined the effects of rituximab treatment for non‐Hodgkin’s lym‐
phoma, and they reported a higher objective response rate in CD16 (158 V) homozygous 
patients compared to CD16 (158F) carrier patients [98]. Wang et al. analyzed the outcomes of 
rituximab treatment for Follicular Lymphoma and reported significantly more likely progres‐
sion‐free survival at 2 years in CD16 (158 V) homozygous patients compared to CD16 (158F) 
carrier patients, at 45 and 14%, respectively [99].
These results suggest that the affinity of CD16 for antibodies correlates with the therapeutic 
effect. Thus, focusing on CD16, the modification of NK cells has been attempted. Binyamin et 
al. reported that introducing CD16 (158 V) into NK‐92 cells not expressing CD16 improved the 
cytotoxicity against B‐cell lymphoma with rituximab [100]. Carlsten et al. reported high ADCC 
activity of cultured NK cells from healthy donors with CD16 (158F/F) and transduced CD16 
(158 V) mRNA by electroporation against rituximab‐coated CD20+ B‐cell lymphoma cells [101].
As described above, since NK cells mediate antibody‐dependent cytotoxic activity via Fc 
receptors, compatibility with antibody drugs targeting ADCC is desirable. As a strategy to 
further augment the antitumor effect, a plausible strategy is to enhance the affinity between 
the Fc receptor and the antibody. Low‐molecular‐weight compounds that are able to inhibit 
the shedding of CD16 have been reported. It is known that CD16 is cleaved by a protease 
such as a disintegrin and a metalloprotease 17 (ADAM17) when cells are activated [102], and 
thus in order to exert more sustained and enhanced ADCC activity, a method of inhibiting 
the cleavage of CD16 on NK cells may be important. In fact, inhibitors of ADAM17 enhanced 
the activity of NK cells [102, 103]. Another method to inhibit the cleavage of CD16 is a genetic 
modification. The substitution of the serine residue at position 197 in CD16 by a proline pre‐
vents the cleavage of CD16 on NK cells [104]. It may be possible to promote the antitumor 
effect by using a CD16 mutant.
4. Optimized selection of patients/donors
4.1. Clinical outcomes: on the KIR ligand mismatch model
Research reports focusing on the KIR of NK cells and the HLA of tumor cells for the purpose of 
treating leukemia have been drawing attention since the 2000′s. In the report by Ruggeri et al. 
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published in Science in 2002, the cases in which HLA‐ABC recognizable by NK cells is present 
in a donor but not in a recipient were defined as “KIR mismatch”. It was speculated that in such 
cases, NK cells not receiving suppression signals from the donor HLA attack the cells of the 
recipient. When Ruggeri et al. started this research, it was not known that NK cells are a het‐
erogeneous population expressing multiple inhibitory receptors, or that the specific antibodies 
that can be used for analysis are inadequate. Ruggeri and colleagues, therefore, examined only 
the HLA of donors and recipients without examining the KIR, and they analyzed patients 
divided into the two groups of HLA matched and mismatched transplantations. Although it 
may not have been an appropriate observation based on the current knowledge, at that time, 
the analysis was based on the following basic research data.
Ruggeri et al. examined whether CD56‐positive NK cell clones collected from donors could 
attack leukemia cells of the recipient. They found that NK cell clones that attack leukemia cells 
exist, and their high frequency (≥2%) correlates well with the cases in which the donor’s and 
recipient’s KIR ligand (HLA) do not match in the GVH direction. Ruggeri et al. analyzed 35 
acute lymphoblastic leukemia (ALL) and 57 acute myeloid leukemia (AML) patients who had 
allogeneic hematopoietic stem cell (HSC) transplantations at their institution. The result was 
a breakthrough result in 20 AML patients who were not KIR ligand mismatches in the GVH 
direction, with 0% relapse after transplantation [105]. This report was the subject of much 
attention, and then it was decided to conduct data analyses in medical institutions around the 
world seeking reproducibility of the results.
The analysis by Ruggeri et al. was by the method known as the “KIR ligand mismatch model”, 
which examines only the donor and recipient HLA‐ABC without checking the KIR. This 
method determines whether a KIR match or mismatch is determined. Researchers all over the 
world could thus easily use this method. However, most of the analysis results obtained in 
this way conflicted with the report by Ruggeri et al.
As an example, we will describe the analysis results obtained from the study of the Japan 
Marrow Donor Program (JMDP). In 2007, Morishima et al. reported the results of their analy‐
sis of 1790 patients who underwent an allogeneic bone marrow transplantation in accord with 
the KIR ligand mismatch model [106]. In conventional domestic allogeneic HSC transplanta‐
tion, the criterion for donor selection is that the HLA‐AB and ‐DR matched, and by this crite‐
rion 534 of the 1790 cases were HLA‐C mismatched. As a result, the overall survival rate, the 
recurrence rate, and the incidence of GvHD were poor in the group in which the KIR ligand 
HLA‐C was mismatched in the GVH direction.
The finding that allogeneic HSC transplantation has no merit in KIR mismatches is common 
in the report about cases from the U.S. National Marrow Donor Program (NMDP) and the 
European group for blood and marrow transplantation (EBMT) [107]. Comparing Ruggeri’s 
2002 report with Morishima’s 2007 report, the biggest difference was the cell source for trans‐
plantations, the former being CD34+ cell transplantation from haploidentical donors and the 
latter being conventional bone marrow transplantation. In addition, Ruggeri et al. used anti‐
thymocyte globulin (ATG) in all cases. A re‐analysis of the registered JMDP cases reconfirmed 
that the transplantation performance of the HLA‐C matched group was also good and that of 
the group with the HLA‐C mismatch was poor [108].
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Interestingly, the disadvantage of this HLA‐C mismatch was not observed in the ATG admin‐
istration group. In other words, it is suggested that not NK cell dysfunction but T cells induced 
by HLA‐C mismatch had exacerbated the transplantation results. T cell‐depleted grafting and 
ATG might avoid the T‐cell response. There are certain reports that HLA‐C mismatches are 
recognized by cytotoxic T lymphocytes (CTLs). There are two papers that reported a total 
of nine CTL clones from two patients who developed GvHD [109, 110]. Interestingly, all of 
the targets of the nine CTL clones were HLA‐C, which was different from the HLA‐C of the 
recipient. There is no doubt that the difference in HLA‐C could be a target for CTL.
4.2. Receptor ligand model or missing ligand model
Although the KIR ligand mismatch model investigated only ligand (i.e., HLA) differences, 
eventually some researchers noted that donors’ KIR should also be examined and analysed 
by different approaches were developed. In 2004, Leung et al. analyzed 36 children who 
received selective CD34+ cell transplantation from haploidentical donors [111]. They first 
examined the presence or absence of inhibitory KIR in donor cells by flow cytometry (i.e., 
a phenotype assay). It was speculated that the recipient would have a KIR mismatch if the 
recipient did not have a ligand for KIR (suppressing type) of the donor. This is the “recep‐
tor‐ligand model”.
For example, when the donor has KIR2DL1 with HLA‐C1/C1, when the recipient is  HLA‐
C1/C1, it is considered a KIR match in the KIR ligand mismatch model, but it is a ligand 
mismatch of KIR2DL1 in the receptor‐ligand model. This is a very frequent combination 
for Japanese (HLA‐C1/C1 = 85%, KIR2DL1+ = 99%). Conversely, if the donor does not have 
KIR2DL1 with HLA‐C1/C2, if the recipient is HLA‐C1/C1, it is considered a KIR mismatch 
in the KIR ligand mismatch model, but it is considered a KIR match in the receptor‐ligand 
model. However, since there are few KIR2DL1− and HLA‐C1/C2 among Japanese, this com‐
bination is extremely rare.
An analysis conducted to determine which model can predict recurrence more accurately 
revealed that the receptor‐ligand model is superior [111]. Hsu et al. also reported their analy‐
sis based on the receptor‐ligand model [112]. They investigated 178 cases of T cell‐depleted 
transplantation and found that the positive rates of KIR2DL1, KIR2DL2/3, and KIR3DL1 were 
93, 99, and 92%, respectively, in the donor gene, and that although there were 112 cases (63%) 
of the 178 patients who were expected to exhibit the GVL effect, there was a significant dif‐
ference in the recurrence rate, and the disease‐free survival rate/overall survival rate was also 
good in the AML and myelodysplastic syndrome (MDS) patients.
Hsu et al. presented a new idea in 2006 [113]. It is hard to examine the donor’s KIR by genetic 
testing, but donors usually have genes of KIR2DL1, KIR2DL2/3, and KIR3DL1. Therefore, 
HLA‐C1/C1 homozygous, HLA‐C2/C2 homo and HLA‐Bw6/Bw6 homo patients identified 
by examining only the recipient’s HLA may experience the GVL effect from donor NK cells. 
This method is called the “missing ligand model”. It was designed for transplantation perfor‐
mance analyses, not for donor selection. Hsu et al. analyzed 1770 patients who had allogeneic 
(unrelated) T‐cell‐depleted transplantation. A University of Minnesota study examined 2062 
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cases from the U.S. NMDP [114], and based on the idea that NK cells have a GVL effect, 
they excluded 568 Japanese subjects or analyzed only partial diseases with good prognosis. 
Nonetheless, that paper is very interesting as it shows the difference in the distribution of KIR 
ligand between Japanese and Westerners and the difference in the recurrence rate of disease 
[113]. We can see how Japanese are ‘biased’ toward HLA‐C1.
Although few cases of GvHD in Japanese have been reported, the recurrence rate of HLA‐C1/
C1 patients is not much different from that of Westerners. In addition, among the Japanese, the 
recurrence rate is extremely small when the recipients are HLA‐C2/C2 homozygous, which is 
a minority. However, caution is required in the interpretation of the results, as there are only 
three cases in which the recipient had HLA‐C2/C2. Further detailed analysis is expected in 
the future.
4.3. Therapeutic effects of allogeneic transplantation of NK cells, and their limitations
In 2007, Ruggeri et al. reported the results of 122 cases of AML [115], which included 57 cases 
[105] and the other 55 cases. In the KIR ligand mismatch model, there were 51 cases of KIR 
mismatch in the GVH direction and 61 cases of matches, and the number of remission cases 
at the time of transplantation and the cases which were refractory to treatment were approxi‐
mately 50% of the cases. The results showed that although the relapse rate was significantly 
lower in the cases of remission at the time of transplantation in the KIR mismatch in the GVH 
direction (3 vs. 47%, p = 0.003), in the cases in which the treatment was refractory, no treat‐
ment effect was observed (32 vs. 37%, p = NS).
Is it true that NK cells exert a GVL effect? A direct answer to that question has been reported 
as a KIR‐mismatch NK cell transplantation in recent years. Ten children with AML [7] and 13 
adults with AML [116] underwent the transplantation of CD56‐positive NK cells harvested 
from haploidentical donors. The collected NK cells were considered KIR mismatches, and 
in both studies, only NK cells were transplanted after pretreatment (fludarabine and cyclo‐
phosphamide). The number of transplanted NK cells was 29 × 106/kg for the children and 2.7 
× 106/kg for the adults; the numbers of transplanted T cells were <1 × 103/kg and < 1 × 105/kg, 
respectively. After transplantation, 1–10 million units of IL‐2 were administered every other 
day, 6 times.
As a result, transient engraftment of donor NK cells was observed in all cases. Donor‐derived 
NK cells occupied 7% (1–30%) of the peripheral blood lymphocytes at the peak of day 14 in 
the children’s report, and at day 28, donor‐derived NK cells have been detected from three of 
10 patients [7]. All of the child patients had AML in complete remission, and all cases did not 
recur. Among the adult patients, whose leukemia was worse, one of five patients with clear 
recurrence showed transient remission, and two patients with genetic recurrence AML were 
remitted [116]. From the above results, it was demonstrated that NK cells exert a sufficient 
antitumor effect if the residual tumor is relatively small. However, it is not yet clear whether 
the therapeutic effect is proportional to the number of NK cells administered. It should be 
noted that even though transplanted CD3‐positive cells are limited to ≤1 × 103/kg, there was 
no case of GvHD onset in either group.
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4.4. Selection of KIR in allogeneic hematopoietic stem cell transplant donors
The target diseases in which the therapeutic effect by NK cells is confirmed in analyses of vari‐
ous clinical tests are mostly limited to AML. Clinical trials using conventional NK cells often 
do not even target other diseases. There are reports that NK cells do not show a therapeutic 
effect against ALL because of lymphoid cells highly MHC class I, and therefore, the inhibi‐
tory signal is strong [117]. In addition, KIR ligand mismatch can lead to GvHD by CTLs as 
described above. In order to avoid this, ingenuity such as umbilical cord blood transplanta‐
tion or the use of ATG may be necessary.
4.4.1. Donor selection based on inhibitory receptors
There is a reason to expect the GVL effect in donor NK cells not receiving a KIR signal from 
the recipient HLA. The main inhibitory receptors are KIR2DL1, KIR2DL2/3, KIR3DL1, and 
KIR3DL2. There is no evidence that the effects of these four inhibitory receptors are identical. 
Particularly with regard to KIR3DL2, there are reports that the KIR‐positive NK cells are not 
even licensed, even if the recipient has HLA‐A3 or A11 (KIR3DL2 ligands) [118]. Most NK 
cell transplantations have been expected to provide a therapeutic effect due to missing self of 
KIR2DL1 or KIR2DL2/3, and the number of transplantations in which a therapeutic effect by 
missing self of KIR3DL1 have been expected is very low. There is no transplantation in which 
the therapeutic effect by missing self of KIR3DL2 alone is expected.
For example, if the recipient is HLA‐C1/C1 if the KIR ligand mismatch model is used, an 
HLA‐C1/C2 or HLA‐C2/C2 donor would be selected. Even if transplantation is assessed 
using the receptor‐ligand model, the donor’s KIR is often unknown. However, in Japanese, 
most (approx. 99%) donors KIR2DL1 can be considered positive. If so, in the receptor‐ligand 
model, it seems that any donor could be chosen, but NK cells derived from an HLA‐C1/C1 
donor may show a lower GVL effect. When the recipient is HLA‐Bw6/Bw6, it must first be 
confirmed that all of the HLA‐A23, ‐24 and ‐32 are negative, and then an HLA‐Bw4‐positive 
donor should be selected. However, since 7% of Japanese are negative for KIR3DL1 gene, 
it must be confirmed that KIR3DL1 is positive for the donor by flow cytometry, or that the 
genotype is either KIR3DL1*01502 or KIR3DL1*020.
4.4.2. Donor selection based on haplotypes
It was reported that donors should be chosen for haplotype B when considering the activat‐
ing receptors [34]. In that study, Cooley et al. analyzed 448 AML cases of NMDP, and they 
observed that the 3‐year overall survival rate when the donor was haplotype BX was 31%, 
significantly higher than the rate of 20% when it was haplotype AA (p < 0.01). In addition, the 
recurrence decreases the most in cases that the donor had Cen‐B/Cen‐B, and it is reported that 
Tel‐B also leads to a reduction of recurrence and improvement of prognosis [119].
Based on the data from three groups in the United States (Memphis, Sloan Kettering, 
Minnesota), Leung et al. advocated a donor selection algorithm for NK cells [120]; in the trans‐
plantation of T cells containing bone marrow or peripheral blood stem cells, donors should 
be HLA matches, and donors with KIR ligand mismatch should be avoided. Conversely, in 
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T cell‐depleted transplantation or umbilical cord blood transplantation, a donor for a KIR 
ligand mismatch should be chosen. It is also recommended that a donor with KIR that can 
attack the recipient’s HLA (possibly KIR haplotype B) be selected. In Japan as well, if KIR hap‐
lotype testing of the donor banks becomes possible in the future, or if the NK cell preparation 
is put to clinical use, it will be possible to test this algorithm described by Leung et al.
4.4.3. Donor selection based on activating receptor
KIR2DS1 is activated by HLA‐C2. This means that if the recipient is positive for HLA‐C2 
and the donor is KIR2DS1‐positive (Tel‐B = haplotype BX), KIR2DS1‐positive NK cells will 
be activated and will kill the recipient’s tumor cells. In actual transplantation, when NK cells 
were cultured in vitro to examine the antitumor effect on leukemic cells of patients, KIR2DS1‐
positive NK cells killed tumor cells of recipients with HLA‐C2 [121]. An analysis of the KIR 
gene of AML donors and recipients (1277 cases) from the U. S. NMDP and the Center for 
International blood and marrow transplant research (CIBMTR) provided large‐scale proof 
using actual transplantations, and the report was published in The New England Journal of 
Medicine [122]. The analysis revealed that recurrence was significantly reduced when the donor 
had KIR2DS1 (26.5 vs. 32.5% (KIR2DS1‐negative), p = 0.02). However, this effect was canceled 
when the donor was HLA‐C2/C2. This is thought to be a disarming phenomenon, and it can 
be explained as follows: the HLA‐C2/C2‐derived KIR2DS1‐positive clone is inactivated.
In that report [122], the proportion of donors with the KIR2DS1 gene was 33%. In the report 
by Yabe et al. [108], the KIR2DS1 gene‐positive rate was 38%. Since Yabe et al. focused only on 
recipients of HLA‐C2/C2, they did not analyze KIR2DS1‐positive donors because the number of 
cases was too small. In addition, it was reported that when the donors had KIR3DS1, although 
a decrease in the recurrence rate was not observed, the mortality rate decreased slightly [122]. 
Yabe et al. also analyzed leukemia patients and reported that transplantation from KIR3DS1 
donors reduced the rate of acute GvHD [123]. It was also reported that the likelihood of acute 
GvHD increases when the donor is haplotype AA [124, 125]. The mechanisms underlying KIR/
HLA interactions remain unclear, but these reports may be a reference for donor selection.
4.5. Immune checkpoint inhibitors
4.5.1. Checkpoint of NK cells
Checkpoint inhibitors are an extremely promising approach among immunotherapies. 
Treatment with anti‐CTLA4 or anti‐PD‐1 antibody restored the T‐cell activity in cancer patients 
and resulted in tumor regression in several patients. A combination of both of the checkpoint 
inhibitors anti‐CTLA4 and anti‐PD‐1 could further enhance therapeutic benefits [126, 127]. It 
has been shown that NK cells from patients with multiple myeloma and renal cancer express 
PD‐1, the signal of which reduce the cytolytic activities of NK cells [128, 129]. Treatment using 
patient‐derived PD‐1+ NK cells with the anti‐PD‐1 antibody (pidilizumab, CT‐011) increased 
the NK cell‐mediated killing of autologous cancer cells in vitro [128]. The therapeutic benefit 
of activating PD‐1+ NK cells in cancer patients is currently not well understood, and the major 
therapeutic effect is certainly due to the re‐activation of exhausted T cells.
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4.5.2. Combination with a checkpoint inhibitor: expansion of the therapeutic spectrum
A loss or down‐regulation of HLA class I antigens in tumor cells has been frequently observed 
in a variety of human malignancies, and this represents an important cancer‐immune escape 
mechanism [130–134]. Using a panel of monoclonal antibodies on tumor tissue sections, these 
loss or down‐regulation has been found in 60–90% of tumors [135–140]. Early studies using 
immunohistological analyses of different tumors showed a very low frequency of allelic loss. 
However, with the arrival of other techniques, such as studies of microsatellites to detect 
the loss of heterozygosity (LOH) on chromosome 6, it has been shown that LOH (haplotype 
loss) is the most frequent alteration of HLA class I expression [139, 141–144]. This alteration 
is caused by various defects in the HLA genomic region (i.e., the short arm of chromosome 
6, 6p21), including chromosomal dysfunction, mitotic recombination, and genetic conversion.
The nature of the antigens that allow the immune system to distinguish cancer cells from non‐
cancer cells has long remained obscure. Recent technological innovations have made it possi‐
ble to dissect the immune response to patient‐specific neoantigens that arise as a consequence 
of tumor‐specific mutations, and emerging data suggest that the recognition of such neoanti‐
gens is a major factor in the activity of clinical immunotherapies. These observations indicate 
that the neoantigen load may form a biomarker in cancer immunotherapy and provide an 
incentive for the development of novel therapeutic approaches that selectively enhance T‐cell 
reactivity against this class of antigens.
If there is a neoantigen that can be a target of CTL and the patient has MHC on which the 
antigen is presented, and if the MHC is not lost from the tumor cells, treatments using CTL as 
an effector (e.g., checkpoint inhibitors) may be effective. NK cells that preferentially kill tumor 
cells whose expression of MHC has decreased by MHC non‐restriction are expected to have a 
synergistic effect with a checkpoint inhibitor.
5. Future directions
5.1. Genetic modification–Gene transfer to NK cells
In order to genetically modify NK cells, efficient methods for gene transduction into NK cells 
are necessary. To date, such methods include viral transduction, electroporation, and nucleo‐
fection [145]. Gene transfer to not only NK cell lines such as NK‐92, but also primary NK 
cells has been conducted. Although various gene transfer efficiencies have been described, 
their transduction efficiency into NK cells is generally not high. Mainly retroviral vectors and 
lentiviral vectors are used for gene transfer. Since a retrovirus vector cannot transduce genes 
into non‐dividing cells, such a vector is suitable for use with NK cell lines such as NK‐92 cells. 
When a retrovirus vector is used for primary NK cells, it is necessary to amplify the NK cells, 
and the transduction timing is important.
In contrast, lentiviral vectors are capable of gene transfer into both dividing and non‐dividing 
cells. The lentiviral vectors RD114, 10A1, GALV, and VSV‐G are used for the envelope of the 
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viral vector, and RD114 and VSV‐G seem to be suitable. However, it has been reported that 
viral vectors are recognized by antiviral mechanisms such as intracellular pattern recognition 
receptors, and apoptosis is induced [146]. The introduction efficiency was therefore not high.
Efforts are underway to improve the transduction efficiency. For example, by using a cytokine 
combination (e.g., IL‐2 + IL‐15 or IL‐2 + IL‐21), the transduction efficiency into NK cells by 
VSV‐G pseudotyped lentiviral vector was improved by approx. fivefold compared to single 
cytokine‐stimulated NK cells [146]. In addition, inhibitors of intracellular antiviral responses 
were evaluated, and the results indicated that BX795 (an inhibitor of the TBK1/IKKe com‐
plex) improved the transduction efficiency by approx. 10‐fold [146]. Guven et al. reported 
transduction into 75.4% of NK cells after 21 days of culture by a two‐round transduction with 
the GALV‐pseudotyped retroviral vector [147]. Further improvement of the transduction effi‐
ciency into NK cells by using viral vectors is desired.
In non‐viral gene transfer, mainly electroporation has been studied. Electroporation is a 
method of physically pulling a minute hole in a cell membrane by applying an electric pulse 
to a cell suspension and sending the nucleic acids into the cells. The transfer of genes into NK 
cells using this method has been performed. High transfection efficiency and a high survival 
rate have been reported in both NK cell lines and primary NK cells. Much higher transfection 
efficiency was achieved using mRNA compared to using DNA [148–152]. Introduction by 
nucleofection has also been tried, but the efficiency was not high [153, 154].
In light of these reports, the transfection of mRNA by electroporation is considered to 
be an efficient method from the viewpoint of gene transfer into NK cells. Shimasaki and 
colleagues reported that NK cells transfected with mRNA encoding CD19‐specific CAR 
(anti‐CD19‐4‐1BB‐CD3ζ) by electroporation showed enhanced cytotoxicity for tumors in 
animal models [154]. On the other hand, the transfection of mRNA can obtain transient 
gene expression. Further research is required to determine whether a treatment effect can 
be expected. When persistent gene expression is the goal, gene transfer by retroviral or 
lentiviral vectors is suitable.
It is necessary to select a suitable gene transfer method for the purpose of treatment. In any 
case, it is desirable to develop more efficient, simple, highly reproducible and clinically appli‐
cable gene transfer methods for NK cells.
5.2. Improved persistence of NK cells in vivo
As a strategy for the genetic modification of NK cells to improve their survival in vivo, meth‐
ods for transducing cytokines such as IL‐2 and IL‐15 into NK cells have been reported, since 
it was demonstrated that a local administration of IL‐2 resulted in enhanced functioning of 
NK cells [155, 156]. IL‐15 has already been used in patients with metastatic melanoma and 
metastatic renal cell carcinoma, and it has been reported to induce the proliferation and clini‐
cal response of NK cells. Following these findings, attempts to introduce IL‐2 and IL‐15 genes 
into NK cells were reported. Nagashima et al. showed that the NK‐92 cell line transduced 
with IL‐2 genes with a retroviral vector propagated for >5 months irrespective of IL‐2 and 
showed higher antitumor activity than the parental cell line in vitro and in vivo [157]. Imamura 
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et al. showed that the transfection of membrane‐bound IL‐15 into human PBMC‐derived NK 
cells using a retroviral vector resulted in the cells’ survival for 2 months without the addition 
of cytokines in vitro, and that the cytotoxicity of the transduced NK cells was enhanced; more‐
over, the antitumor activity was observed in a mouse model [158].
Sahm et al. transduced IL‐15 gene into NK‐92 cells and observed cell proliferation in the 
absence of cytokines. They also showed that the co‐transduction of an EpCAM‐specific chi‐
meric antigen receptor and IL‐15 into NK‐92 cells enhanced the specific and efficient cytotoxic 
activity [159]. Jiang et al. reported high cytotoxic activity of a human NK cell line (NKL) 
transduced with IL‐15 in vitro against human hepatocellular carcinoma; the transduced NKL 
suppressed tumor growth and prolonged survival in human hepatocellular carcinoma‐trans‐
planted model mice [160]. These reports suggested that NK cells transduced IL‐2 or IL‐15 can 
proliferate sustainably in vitro and in vivo, which resulted in improved antitumor activity.
5.3. Improvement of homing
It was reported that NK cells expressed different chemokine receptors depending on the acti‐
vating state [161, 162]. Proper homing to the tumor tissue is an important factor in eliciting the 
antitumor activity of NK cells. Carlsten et al. showed that ex vivo expanded NK cells derived 
from PBMCs transfected with CCR7 mRNA using electroporation migrated significantly to 
CCL19, a ligand of CCR7 [163]. Sonamshi et al. reported that NK cells transferred CCR7 pro‐
tein from feeder cells using trogocytosis, but not genetic manipulation, promoted the migra‐
tion to CCL19 and CCL21 in vitro, and that the NK cells were transferred to lymph nodes in a 
mouse model [101]. There are few reports of genetic modification targeting homing receptors, 
but further progress in this field is expected.
5.4. Improvement of tumor‐specific cytotoxic activity
As an approach to enhance specificity to tumor cells, a technique using a chimeric antigen 
receptor (CAR) should be mentioned. CAR is a chimeric protein composed of a single‐chain 
antibody (the antigen‐specific binding site) in which a light chain and a heavy chain derived 
from a monoclonal antibody recognize a tumor cell surface antigen, a transmembrane domain, 
and an intracellular signal domain.
In the first‐generation CARs, the intracytoplasmic signal domain is composed of only the 
CD3ζchain. In addition to CD3ζ, the second‐generation CARs have another T cell costimula‐
tory signal domain (CD28, 4–1BB, OX40, etc.), and the activation signal is efficiently transmit‐
ted. In the third‐generation CARs, two or more costimulatory signal domains are inserted. 
CAR‐introduced T cells have already been used clinically, and excellent results have been 
obtained in some cases [164–167]. One of the problems with CAR‐T cell therapy is a serious 
side effect. CAR‐T cells attack not only target cells but also non‐target normal cells. For exam‐
ple, CD‐19 CAR‐T cells kill not only tumor cells but also normal B cells, which cause B‐cell defi‐
ciency [168]. In HER2‐specific CAR therapy for colorectal cancer with lung metastasis, death 
due to a pulmonary complication accompanied by high cytokinemia has been reported [169].
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NK cells are an attractive alternative to T cells, as NK cells have the following advantages. 
HLA matching is not necessary, and NK cells are used as allogenic cells. Their lifespan is 
limited, and they can be expected to be excluded from the body before severe side effects 
occur, after they kill cancer cells. The reported CAR‐NK cells are summarized in Table 3. 
NK cells transduced with CD19‐CAR or CD20‐CAR have been used when targeting B‐cell 
malignancies. Bossel et al. showed that NK‐92 cells transfected with anti‐CD19‐CAR by using 
electroporation had high cytotoxic activity against a CD19+ cell line and primary chronic lym‐
phocytic leukemia (CLL) [150]. They also showed that tumor cells can be eliminated in xeno‐
graft mouse models by using NK‐92 cells transduced with anti‐CD19 CAR with lentiviral 
vectors [170]. Imai et al. also showed that primary NK cells transduced with anti‐CD19–CD3ζ 
with a retroviral vector killed CD19+ cells and that the cytotoxicity was improved by adding a 
signaling domain of 4–1BB to anti‐CD19–CD3ζ [171].
NK cell type Target antigen Cancer Co‐stimulatory 
domain
Gene transfer method Ref
NK‐92 cell line ErbB2 (HER‐2) Breast, ovarian 
carcinoma
CD3ζ Retrovirus [175]
NK‐92 cell line CD20 B‐ALL, CLL CD3ζ Retrovirus [170]
NK‐92 cell line CD19 B‐ALL, CLL CD3ζ Electroporation 
(mRNA)
[151]
NK‐92 cell line EpCAM Breast carcinoma CD28/CD3ζ Lentivirus [160]
NK‐92 cell line HLA‐A2 EBNA3C EBV+ T‐cell 
Lymphoma
CD28/CD3ζ Retrovirus [178]
NK‐92 cell line GD2 Neuroblastoma CD3ζ Retrovirus [179]
NK‐92 cell line CD19/CD20 B‐ALL, CLL CD3ζ Electroporation 
(plasmid DNA)
[180]
Lentivirus
NK‐92 cell line CD19/CD20 B‐ALL, CLL CD3ζ Lentivirus [68]
NK‐92 cell line CS1 Multiple myeloma. CD28/CD3ζ Lentivirus [181]
NK‐92 cell line CD138 Multiple myeloma CD3ζ Lentivirus [182]
NK‐92 cell line ErbB2 (HER‐2) Breast carcinoma CD28/CD3 Electroporation 
(plasmid DNA)
[176]
NK‐92 cell line ErbB2 (HER‐2) Breast, ovarian and 
renal cell carcinoma
CD3ζ Lentivirus [183]
CD28/CD3ζ
CD137/CD3ζ
YTS cell line PSCA Prostate cancer CD3ζ Lentivirus [184]
DAP12 TM and 
signaling
YT cell line CD33 AML CD3ζ Electroporation 
(plasmid DNA)
[150]
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The gene human epidermal growth factor receptor 2 (HER2) is overexpressed in many breast 
cancers and is correlated with disease progression [172, 173]. It is therefore considered one of 
the suitable targets of CAR. Kruschinski et al. transduced anti‐HER2–CD28‐CD3ζ into human 
primary NK cells using a retroviral vector, and the results demonstrated cytotoxicity to an 
HER2+ cell line. This cytotoxicity was correlated with the HER2 expression level on target cells 
[174]. Uherek et al. reported that anti‐HER2–CD3ζ‐CAR retrovirally transduced NK‐92 cells 
efficiently killed cell lines derived from ErbB2‐positive breast carcinoma, ovarian carcinoma, 
and squamous cell carcinoma in vitro and in vivo [175]. In a study by Liu et al., the plasmid 
coding anti‐HER2–CD28‐CD3ζCAR was transfected into NK‐92 cells by electroporation, and 
the cells specifically killed the ErbB2‐expressing human breast cancer cell lines MDA‐MB‐453 
and SKBr3. The adoptive transfer of NK‐92 cells specifically reduced the tumor size and lung 
metastasis of nude mice transplanted with MDA‐MB‐453 cells and significantly prolonged 
the survival of these mice [176].
As shown in Table 3, CAR against various tumor‐associated antigens (TAA) has also been 
evaluated in NK cells. Chang et al. reported a modification by CAR using NKG2D, one of the 
human NK cell activating receptors, instead of the antigen‐binding site of the antibody. Since 
NKG2D can bind to eight types of ligands expressed in solid tumors and blood tumors, it can 
be applied to a broader range of tumor cells. Primary human NK cells were transduced with 
a retroviral vector, using constructs designed to combine the extracellular domain of NKG2D 
with CD3ζ and further to express DAP10 simultaneously. This approach showed strong cyto‐
toxic activity against various tumor cell lines and showed no damage to normal cells. It also 
showed strong tumor growth suppression in a mouse model of osteosarcoma [177].
NK cell type Target antigen Cancer Co‐stimulatory 
domain
Gene transfer method Ref
YT cell line CEA Colon carcinoma CD3ζ Electroporation 
(plasmid DNA)
[148]
PBMC‐NK CD19 B‐ALL, CLL CD3ζ Retrovirus [171]
DAP10
CD137/CD3ζ
PBMC‐NK ErbB2 (HER‐2) Breast, ovarian and 
renal cell carcinoma
CD28/CD3ζ Retrovirus [174]
PBMC‐NK CD19/GD2 CD3ζ or 2B4 
alone
Retrovirus [185]
2B4/CD3ζ
CD137/CD3ζ
PBMC‐NK CD19 B‐ALL, CLL CD137/CD3ζ Electroporation(mRNA) [152]
PBMC‐NK CD20 B‐ALL, CLL CD137/CD3ζ Electroporation(mRNA) [186]
PBMC‐NK NKG2D ligands wide range CD3ζ (with 
DAP10)
Retrovirus [177]
Electroporation(mRNA)
Table 3. CAR‐NK cells.
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6. Conclusions
Because NK cells are difficult to culture and it is a challenge to transduce foreign genes into 
NK cells, research concerning NK cells has been delayed compared to research involving T 
cells. However, culture and gene transfer technologies for NK cells are now developing. As 
introduced here, genetically modified NK cells acquired enhanced antitumor functions. These 
NK cells are very intriguing and are expected to be revolutionary cellular medicines for the 
treatment of malignancies.
NK cells are heterogeneous populations that exhibit various maturation stages and different 
KIR expression patterns. Since this heterogeneity has not been completely elucidated, it is 
not easy to choose the appropriate subset of NK cells for cancer treatment. Although alloge‐
neic NK cell therapy using a KIR mismatch shows a strong antitumor effect against several 
blood cancers, the mechanisms underlying the activation and maintenance of NK cells in 
cancer patients are not completely understood. Cancer patients usually undergo a variety 
Gamida Cell 
Lth.
Nant Kwest Inc. Glycostem 
Therapeutics
GreenCross 
LabCell
Fate 
Therapeutics 
Inc.
GAIA 
BioMedicine Inc.
H.Q. Israel USA Netherlands Korea USA Japan
Auto/Allo ??? Allogeneic (Cell 
line)
Allogeneic Allogeneic 
(Health donor)
Allogeneic Allogeneic 
(Haploidentical)
Materials PBMC/BM/
CB
NK‐92 CB CD34+ 
(CliniMACS)
PBMC PBMC 
(CMV+ 
donnor)/iPS
PBMC(CliniMACS 
Prodigy)
Feeder cell − − − Irradiated 
(2000 rad) 
PBMC
− −
Irradiation − Before 
administration
− − − −
Purity >97% (CD3−/
CD56+)
− >98.1 ± 0.88% 
(CD3−/CD56+)
>98.1 ± 0.88% 
(CD3−/CD56+)
>90.9 ± 2.2% 
(CD3−/
CD56+)
>98.0% (CD3‐/
CD56+)
K562 
killing
E:T=1:1, 
40–50%
E:T=5:1 (4 hr), 50% E:T=2:1 (4 hr), 
40%
E:T=10:1 (4 hr), 
70–80%
− E:T=1:1 (2 hr), 
>80%
Handling CPC Wash, Irradiation, 
CPC
CPC CPC CPC Completely closed 
system
Companion 
diagnosis
− − − − − HLA/KIR selection
R & D 
Phase
Non‐
clinical(Phase 
I/II in 2017)
Phase II Phase I Phase II Non‐
clinical(Phase 
I in 2017)
Non‐clinical(Phase 
I in 2017)
Target 
disease
‐ Merkel cell 
carcinoma
AML Hepatocellular 
carcinoma
AML NSCLC, 
Neuroblastoma
Table 4. Products of NK cells for clinical use.
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of standard treatments before receiving immunotherapy, and it is important to understand 
the factors that influence NK cell activity in order to select the correct clinical setting for NK 
cell therapy. In this review, we have explained the combination with antibodies, the genetic 
modification technique, and the KIR mismatch pattern (which is the basis of patient selection) 
that has been tested to maximize the use of NK cells as a treatment for cancer. Products of NK 
cells for clinical use that have been developed worldwide are shown in Table 4.
Advances in the understanding of NK cells may also lead to the development of small‐mol‐
ecule inhibitors targeting intracellular signals. Because NK cells are difficult to handle, their 
development is delayed compared to several other immunotherapies, but it is highly likely 
that they will be established as innovative cell therapy in the near future.
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